Nicholas D. James, MBBS, PhD, of University Hospitals Birmingham NHS Foundation Trust, discusses study findings on the addition of docetaxel to first-line hormone therapy in prostate cancer, an analysis focusing on cost-effectiveness and long-term and quality-adjusted survival (Abstract 162).
Robert G. Bristow, MD, PhD, of Manchester Cancer Research Centre, discusses germline and somatic mutations; new ways to generate biomarkers that may describe tumor complexity; and how, in the future, this information may help triage patients with aggressive prostate tumors to intensified treatments.
Sumanta K. Pal, MD, of the City of Hope Comprehensive Cancer Center, discusses phase III study findings from IMmotion151, which looked at atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (RCC), and results from a safety and efficacy trial of axitinib in combination with pembrolizumab with advanced RCC (Abstracts 578 & 579).
Maha Hussain, MD, of Northwestern University, discusses phase III findings on enzalutamide in men with nonmetastatic castration-resistant prostate cancer (Abstract 3).
Patrick Schöffski, MD, MPH, of Catholic University Leuven, discusses findings on the effect of crizotinib on disease control in patients with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification (Abstract 580).
Eric J. Small, MD, of the University of California, San Francisco, discusses phase III findings on apalutamide vs placebo in patients with nonmetastatic castration-resistant prostate cancer (Abstract 161).
